Heather Lesieur
Physician Assistant · Clayton, CANPI 1891726972
Payments from drug & device makers
Across 158 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$836
- AstraZeneca$260
- Biohaven Pharmaceuticals, Inc.$236
- Amarin Pharma, Inc.$217
- Lilly USA, LLC$146
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$100
- plus $885 from 18 others
What the payments were for
- Food & beverage$2,679100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 56 | $836 |
| AstraZeneca | 11 | $260 |
| Biohaven Pharmaceuticals, Inc. | 9 | $236 |
| Amarin Pharma, Inc. | 30 | $217 |
| Lilly USA, LLC | 6 | $146 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $100 |
| Pfizer | 4 | $99 |
| GSK | 4 | $97 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $88 |
| Bausch Health US, LLC | 4 | $77 |
| Exact Sciences | 3 | $74 |
| Boehringer Ingelheim | 3 | $73 |
| Eisai Inc. | 3 | $59 |
| Novo Nordisk | 3 | $57 |
| Acerus Pharmaceuticals Corporation | 3 | $55 |
| Vanda Pharmaceuticals Inc. | 1 | $37 |
| Merck | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Verity Pharmaceuticals Inc. | 1 | $22 |
| Organon | 1 | $19 |
| Insulet Corporation | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Antares Pharma, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
How this compares
$2,679 in reported general payments places this provider in the 85th percentile of 10,423 physician assistant providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 16 | $23,180 |
| MounjaroTirzepatide | 11 | $10,758 |
| Rosuvastatin Calcium | 92 | $1,687 |
| ValacyclovirValacyclovir Hcl | 23 | $1,327 |
| SynthroidLevothyroxine Sodium | 12 | $1,233 |
| Levothyroxine Sodium | 78 | $1,223 |
| Atorvastatin Calcium | 82 | $1,209 |
| Estradiol | 21 | $1,149 |
| Lidocaine | 13 | $1,090 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $905 |
| Escitalopram Oxalate | 56 | $818 |
| Bupropion XlBupropion Hcl | 34 | $804 |
| Valsartan | 36 | $783 |
| Pregabalin | 30 | $737 |
| Azelastine Hcl | 34 | $665 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $73 | $23,18016 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $146 | $11,15030 claims |
| AbbVieSynthroid | $836 | $1,23312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Clayton
- John QuigleyDowney$2.9M
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
- Shawna JonesFountain Valley$266K
- Heather AustinSalinas$219K
- Eric CheungLos Angeles$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.